PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Warren, NJ. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1.7 billion and a profit of $683 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.3 out of ten, 9 of 9 metrics filed: past 6.7 out of ten, present 5.8 out of ten, future 6.4 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 7.1 out of ten. +30.8% a year over 8 filed years; profitable in 1 of 8. 71st percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 3.9 out of ten. Share count grew 7.2% a year. 0% of cash flow returned. Insiders: 203 sales, 0 purchases. 39th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 3.3 out of ten. Leverage 107%: owes 107¢ per asset dollar. 32nd percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 8.5 out of ten. top 15% of 314 in its family; net margin 39.4%. 85th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 6.8 out of ten. top 32% of 315 in its family for leadership; chief executive since 2023. 68th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 6.1 out of ten. top 39% of 272 in its family for room to expand. 61st percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 5.6 out of ten. top 44% of 307 in its family for growth drivers. 56th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 8.2 out of ten. top 18% of 234 in its family for expectations against reality. 82nd percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-19 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-30 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-30 for the period ended 2026-07-28 (on EDGAR). Newest filing: Form 144, 2026-10-09. Filings on record since 2004. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Collaboration and License Revenue 58%, Royalty 14%, Translarna1 14%, Emflaza 9%, Upstaza and Kebilidi 3%, Other Products 2%. As tagged in its annual report (Form 10-K, filed 2026-02-19).
Who runs it
Klein, Matthew B. (CHIEF EXECUTIVE OFFICER); Gravier, Pierre (CHIEF FINANCIAL OFFICER); Almstead, Neil Gregory (CHIEF TECHNICAL OPS OFFICER); Utter, Christine Marie (SVP, CHIEF ACCOUNTING OFFICER); Pauwels, Eric (CHIEF BUSINESS OFFICER); Golden, Lee Scott (EVP & CHIEF MEDICAL OFFICER); Boulding, Mark Elliott (EXEC. VP AND CLO); Schmertzler, Michael (director); Steele, Glenn Jr Md Phd (director); Sollie-Zetlmayer, Hege Elisabeth (director); and 8 more. 18 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-09.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.